For individuals and families affected by inherited retinal diseases (IRDs), the landscape of treatment and research is continuously evolving, bringing renewed hope. Recent developments highlight significant strides in both small molecule therapies and gene therapy approaches, offering the potential to slow disease progression and restore vision.

Gildeuretinol Shows Promise for Stargardt Disease

Alkeus Pharmaceuticals is making waves with its investigational oral therapy, gildeuretinol, for Stargardt disease. The company announced that data from its clinical studies, including the Phase 2 TEASE study and an overview of the ongoing Phase 3 NORTHSTAR study, will be presented at the American Society of Retina Specialists (ASRS) 44th Annual Meeting from July 15-18, 2026.

Stargardt disease is the most common inherited macular dystrophy, typically causing severe vision impairment in children and young adults due to mutations in the ABCA4 gene. This genetic defect leads to the accumulation of toxic vitamin A dimers, which irreversibly damage the retina and result in progressive vision loss. Currently, there are no FDA-approved treatments for Stargardt disease.

Gildeuretinol is an oral pill designed to reduce the dimerization of vitamin A without disrupting the visual cycle. By slowing the formation of these toxic byproducts, the therapy aims to slow or stop vision loss. Previous studies have shown that gildeuretinol was well-tolerated and demonstrated a statistically significant 15.3% slower lesion growth rate in a pre-specified analysis of a Phase 2/3 study. In some cases, gildeuretinol has even arrested vision loss and retinal pathology progression in presymptomatic individuals with Stargardt disease.

The global Phase 3 NORTHSTAR study is actively enrolling approximately 230 participants aged 8 to 45 with advanced Stargardt disease. This pivotal trial will evaluate gildeuretinol's ability to reduce the growth rate of retinal atrophic lesions and preserve visual acuity, building on positive findings from earlier studies. Gildeuretinol has received several important designations from the FDA, including Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and Orphan Drug, underscoring its potential to address a significant unmet medical need.

Gene Therapy Continues to Advance for Inherited Blindness

Beyond Stargardt disease, gene therapy remains a rapidly advancing field for various forms of inherited blindness. Gene therapy is a compelling approach for IRDs due to their often monogenic nature, meaning they are caused by a single gene defect. The retina is a favorable target for gene therapy due to its unique biological properties.

The approval of Luxturna (voretigene neparvovec-rzyl) for RPE65-associated Leber congenital amaurosis (LCA) marked a historic milestone as the first gene therapy for an IRD. This therapy delivers a functional copy of the RPE65 gene to retinal cells, improving vision and potentially slowing disease progression. While Luxturna has shown encouraging clinical outcomes, particularly in light sensitivity and navigational vision, it does not halt retinal degeneration and is most effective when applied early.

Research continues to explore new gene therapy targets and delivery methods. For instance, a gene therapy for AIPL1-associated retinal dystrophy, a rare and severe form of childhood blindness, has shown promise in restoring vision in young children, with treatment needing to be administered before age four due to rapid degeneration. Scientists are also developing neuroprotective gene therapies that could prevent retinal cell death regardless of the specific genetic mutation, offering a broader treatment approach.

A Future with More Options

These advancements signify a vibrant and hopeful period for the IRD community. The ongoing clinical trials for gildeuretinol in Stargardt disease and the continuous evolution of gene therapies for other inherited blindness conditions underscore a collective commitment to developing effective treatments. As research progresses, patients and their families can look forward to a future with more therapeutic options to preserve and potentially restore sight.